Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 28, 2026

Coca-Cola Reports Second Quarter 2026 Results and Raises Full Year Guidance

View original at finance.yahoo.com
Coca-Cola Reports Second Quarter 2026 Results and Raises Full Year Guidance Global Unit Case Volume Grew 5% Net Revenues Grew 7%; Organic Revenues (Non-GAAP) Grew 6% Operating Income Grew 9%; Comparable Currency Neutral Operating Income (Non-GAAP) Grew 6% Operating Margin was 34.9% versus 34.1% in the Prior Year; Compa…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Coca-Cola delivered another strong quarter by staying close to changing consumer and customer needs, leveraging its brands and system to gain value share while delivering revenue, profit and earnings growth and investing for the long term.

    60% confidence

Data points we hold from this source

The Coca-Cola Company · cash7.5 USD
The Coca-Cola Company · global unit case volume growth5 percent
The Coca-Cola Company · comparable operating income growth6 percent
The Coca-Cola Company · eps1.03 USD
The Coca-Cola Company · margin34.7 percent
The Coca-Cola Company · operating income growth9 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
Coca-Cola Reports Second Quarter 2026 Results and Raises Full Year Guidance — Source | Via News | ViaNews Market